Home » Cardiovascular » EMPA-REG OUTCOMES: Empagliflozin, CV, and Mortality in Type 2 Diabetes

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

EMPA-REG OUTCOMES: Empagliflozin, CV, and Mortality in Type 2 Diabetes

2015, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes, NEJM

Subscribe via email